-
Je něco špatně v tomto záznamu ?
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
VD. de Jager, W. Timens, A. Bayle, J. Botling, L. Brcic, R. Büttner, MGO. Fernandes, L. Havel, M. Hochmair, P. Hofman, A. Janssens, L. van Kempen, I. Kern, JC. Machado, K. Mohorčič, S. Popat, A. Ryška, J. Wolf, E. Schuuring, AJ. van der Wekken
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2021
PubMed Central
od 2021
ROAD: Directory of Open Access Scholarly Resources
od 2020
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.
Charles University and Thomayer Hospital Prague Czech Republic
Department of Oncology University Hospital Antwerp University of Antwerp Edegem Belgium
Department of Pathology University Hospital Antwerp University of Antwerp Edegem Belgium
Diagnostic and Research Institute of Pathology Medical University of Graz Graz Austria
Faculty of Medicine of the University of Porto Portugal
IHU RespirERA FHU OncoAge Nice University Hospital Côte d'Azur University Nice France
Institute for Research and Innovation in Health Porto Portugal
Institute of Medical Genetics and Applied Genomics University of Tuebingen Tuebingen Germany
Institute of Molecular Pathology and Immunology of the University of Porto Porto Portugal
Karl Landsteiner Institute of Lung Research and Pulmonary Oncology Klinik Floridsdorf Vienna Austria
Laboratory for Cytology and Pathology University Clinic Golnik Golnik Slovenia
Lung Unit Royal Marsden NHS Trust London England UK
Oncostat U1018 Inserm Paris Saclay University Gustave Roussy Villejuif France
Pulmonology Department Centro Hospitalar Universitário de São João Porto Portugal
University Clinic of Respiratory and Allergic Diseases Golnik Slovenia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005670
- 003
- CZ-PrNML
- 005
- 20240412130946.0
- 007
- ta
- 008
- 240405e20240301enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.lanepe.2024.100839 $2 doi
- 035 __
- $a (PubMed)38476751
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a de Jager, Vincent D $u Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 245 10
- $a Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer / $c VD. de Jager, W. Timens, A. Bayle, J. Botling, L. Brcic, R. Büttner, MGO. Fernandes, L. Havel, M. Hochmair, P. Hofman, A. Janssens, L. van Kempen, I. Kern, JC. Machado, K. Mohorčič, S. Popat, A. Ryška, J. Wolf, E. Schuuring, AJ. van der Wekken
- 520 9_
- $a For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Timens, Wim $u Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 700 1_
- $a Bayle, Arnaud $u Oncostat U1018, Inserm, Paris-Saclay University, Gustave Roussy, Villejuif, France
- 700 1_
- $a Botling, Johan $u Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden
- 700 1_
- $a Brcic, Luka $u Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Büttner, Reinhard $u Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany
- 700 1_
- $a Fernandes, Maria Gabriela O $u Pulmonology Department, Centro Hospitalar Universitário de São João, Porto, Portugal
- 700 1_
- $a Havel, Libor $u Charles University and Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a Hochmair, Maximilian $u Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria $u Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria
- 700 1_
- $a Hofman, Paul $u IHU RespirERA, FHU OncoAge, Nice University Hospital, Côte d'Azur University, Nice, France
- 700 1_
- $a Janssens, Annelies $u Department of Oncology, University Hospital Antwerp, University of Antwerp, Edegem, Belgium
- 700 1_
- $a van Kempen, Léon $u Department of Pathology, University Hospital Antwerp, University of Antwerp, Edegem, Belgium
- 700 1_
- $a Kern, Izidor $u Laboratory for Cytology and Pathology, University Clinic Golnik, Golnik, Slovenia
- 700 1_
- $a Machado, José Carlos $u Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal $u Faculty of Medicine of the University of Porto, Portugal $u Institute for Research and Innovation in Health (i3S), Porto, Portugal
- 700 1_
- $a Mohorčič, Katja $u University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia
- 700 1_
- $a Popat, Sanjay $u Lung Unit, Royal Marsden NHS Trust, London, England, UK
- 700 1_
- $a Ryška, Aleš $u The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Czech Republic
- 700 1_
- $a Wolf, Jürgen $u Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany
- 700 1_
- $a Schuuring, Ed $u Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 700 1_
- $a van der Wekken, Anthonie J $u Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 773 0_
- $w MED00208007 $t The Lancet regional health. Europe $x 2666-7762 $g Roč. 38 (20240301), s. 100839
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38476751 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130939 $b ABA008
- 999 __
- $a ok $b bmc $g 2075984 $s 1215432
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 38 $c - $d 100839 $e 20240301 $i 2666-7762 $m The Lancet regional health. Europe $n Lancet Reg Health Eur $x MED00208007
- LZP __
- $a Pubmed-20240405
